Yan Lin He, DO
Internal Medicine · Longview, WANPI 1538470331
Payments from drug & device makers
Across 54 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$207
- Pfizer$114
- Johnson & Johnson$109
- Amarin Pharma, Inc.$67
- Merck$61
- Lilly USA, LLC$51
- plus $270 from 9 others
What the payments were for
- Food & beverage$878100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $207 |
| Pfizer | 6 | $114 |
| Johnson & Johnson | 11 | $109 |
| Amarin Pharma, Inc. | 4 | $67 |
| Merck | 4 | $61 |
| Lilly USA, LLC | 3 | $51 |
| Astellas Pharma US Inc | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 2 | $47 |
| Amgen | 3 | $43 |
| Metuchen Pharmaceuticals | 2 | $38 |
| GSK | 1 | $23 |
| AstraZeneca | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| AbbVie | 1 | $12 |
How this compares
$878 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PradaxaDabigatran Etexilate Mesylate | 170 | $45,319 |
| OzempicSemaglutide | 60 | $44,404 |
| Spiriva RespimatTiotropium Bromide | 48 | $33,926 |
| XareltoRivaroxaban | 35 | $28,837 |
| JardianceEmpagliflozin | 53 | $20,016 |
| Humulin NInsulin Nph Human Isophane | 104 | $17,486 |
| Wixela InhubFluticasone Propion/Salmeterol | 49 | $11,724 |
| Atorvastatin Calcium | 918 | $10,318 |
| Gabapentin | 341 | $8,748 |
| Insulin Glargine-Yfgn | 60 | $8,326 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $8,235 |
| Levothyroxine Sodium | 477 | $8,133 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 322 | $7,768 |
| Lisinopril | 622 | $7,343 |
| Humulin RInsulin Regular, Human | 53 | $6,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimPradaxa, Spiriva Respimat, Jardiance, Stiolto Respimat | $207 | $107,496282 claims |
| Johnson & JohnsonXarelto | $109 | $28,83735 claims |
| Lilly USA, LLCHumulin N, Humulin 70-30, Humalog | $51 | $25,409144 claims |
| GSKShingrix | $23 | $5,60028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Longview
- Richard KirkpatrickLongview$19K
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.